FDA-Approved Devices Reach Brazil Years Later, While Some Were Registered There First

Two Medtronic cardiac devices had ANVISA registrations published on September 21, 2026, about 35 and 17 months after FDA approval, while BAGUERA C, Belotero and SELUTION SLR were registered in Brazil or Colombia before their 2026 FDA approvals.

Two institutional building silhouettes representing regulatory bodies face each other across a wide canal divided by a gate, with a medical device shape — a flat geometric rectangle with small connector nodes — already positioned on the right side while an identical shape waits behind a closed barrier on the left, illustrating an asymmetric approval pathway between two countries.

MEDTECH ACCESS TRACKER · MEDICAL DEVICES · OCTOBER 2, 2026 · BRAZIL · COLOMBIA · US

Two Medtronic cardiac rhythm products had registrations published by Brazil’s National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA) on September 21, 2026, well after their US approval. The gap does not always run in one direction: several devices that the FDA approved in 2026 were already registered in Brazil or Colombia years earlier.

~35 months

Time between the FDA premarket approval (PMA) of Medtronic’s Aurora EV-ICD system on October 20, 2023 and the publication of its ANVISA registration on September 21, 2026.

FDA-approved devices: how long until Brazil?

  • Aurora EV-ICD (extravascular implantable cardioverter-defibrillator) system: FDA PMA on October 20, 2023; ANVISA registration 10349001360 published September 21, 2026, about 35 months later.
  • OmniaSecure defibrillation lead: FDA PMA on April 22, 2025; ANVISA registration 10349001362 published September 21, 2026, about 17 months later.

Sometimes Latin America comes first

  • BAGUERA C cervical disc prosthesis (Spineart): FDA PMA on August 10, 2026, while a Spineart cervical disc registration whose model codes match the BAGUERA C implant range has been active in Brazil since February 20, 2017 (ANVISA 81000030038, listed under the generic name “Prótese de Disco Cervical”).
  • Belotero Volume and Belotero Intense (with lidocaine), Merz dermal fillers that received original FDA PMAs in May and July 2026 respectively, have been registered in Brazil as Belotero Volume Lidocaine and Belotero Intense Lidocaine since April 1, 2019 (ANVISA 80829430009 and 80829430008).
  • SELUTION SLR sirolimus drug-eluting balloon, approved by the FDA on September 18, 2026 for coronary in-stent restenosis, has held a valid registration for its coronary version in Colombia since 2023 from the National Food and Drug Surveillance Institute (Instituto Nacional de Vigilancia de Medicamentos y Alimentos, INVIMA), with Cordis as holder.

New FDA approvals, August–September 2026

Of 11 devices the FDA authorized through original PMA or De Novo classification in August and September 2026, two were already registered in Latin America before the US decision (BAGUERA C in Brazil and SELUTION SLR in Colombia). The other nine were not found in the public registers of ANVISA or INVIMA as of October 2, 2026.

FDA approval vs. Latin American registration

Device FDA decision Latin American registration Gap
Aurora EV-ICD (Medtronic) Oct 20, 2023 Brazil, published Sep 21, 2026 ~35 months after FDA
OmniaSecure lead (Medtronic) Apr 22, 2025 Brazil, published Sep 21, 2026 ~17 months after FDA
BAGUERA C (Spineart) Aug 10, 2026 Brazil, since Feb 20, 2017 Before FDA
Belotero Volume (Merz) May 2026 Brazil, since Apr 1, 2019 Before FDA
Belotero Intense (Merz) Jul 2026 Brazil, since Apr 1, 2019 Before FDA
SELUTION SLR 014 (MedAlliance) Sep 18, 2026 Colombia, since 2023 Before FDA

Sources: FDA PMA database; ANVISA and INVIMA open data

What to Watch

  1. Whether the nine devices approved by the FDA in August and September 2026 appear in ANVISA or INVIMA registers in the coming months; HealthSignals tracks both registers monthly
  2. Further Medtronic cardiac rhythm registrations in Brazil following the Aurora EV-ICD and OmniaSecure filings
  3. How companies sequence US and Latin American filings for devices already on the market in the region
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

Method note: FDA data from openFDA (original PMAs and De Novo grants). Brazil from ANVISA’s open dataset of registered health products (publication date of the registration). Colombia from INVIMA’s open dataset on datos.gov.co, which reports registration status but not grant dates; the year shown comes from the registration number. “Not found” means not found in the public register on the date checked; it does not mean no application exists. Months = days ÷ 30.44.

Sources: FDA PMA P220012 (Aurora EV-ICD) · FDA PMA P240036 (OmniaSecure) · FDA PMA P250042 (BAGUERA C) · FDA PMA P250020 (Belotero Volume) · FDA PMA P250016 (Belotero Intense) · FDA PMA P250041 (SELUTION SLR) · openFDA device APIs · ANVISA open data (TA_PRODUTO_SAUDE_SITE.csv, TA_PRODUTO_SAUDE_MODELO.csv) · INVIMA medical device registrations (datos.gov.co) · Spineart: BAGUERA C product brochure

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related